Nov 07, 2025 This Week in Cardiology

This Week in Cardiology

Medscape Podcasts

Science, Medicine, Health & Fitness

4.9 • 963 Ratings

🗓️ 7 November 2025

⏱️ 32 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

Meta-analysis of MI as a surrogate https://pubmed.ncbi.nlm.nih.gov/34694318/
Compare Acute Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1701067
DANAMI-3–PRIMULTI 10.1016/S0140-6736(15)60648-1 External Link
CULPRIT-SHOCK https://www.nejm.org/doi/full/10.1056/NEJMoa1710261

II Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST

PISCES Trial www.nejm.org/doi/full/10.1056/NEJMoa2513032
REDUCE-IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
STRENGTH Trial https://jamanetwork.com/journals/jama/fullarticle/2773120
FISH trial https://jamanetwork.com/journals/jama/fullarticle/1150094

III Obesity Agents

White House announces deal with Lilly and Novo on GLP-1 drugs https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/

Amylin Agonists

Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial

https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf

Eloralintide Phase 2 Study https://doi.org/10.1016/S0140-6736(25)02155-5

GLP-1 Comparisons

SURMOUNT-5 Trial https://www.nejm.org/doi/10.1056/NEJMoa2416394
Tirzepatide vs Semaglutide in 10-year CVD Risk Reduction https://doi.org/10.1093/ehjopen/oeaf117

IV A Problematic Trial in Stroke Care

LAMP trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370

V AHA Preview

AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Transcript

Click on a timestamp to play from that location

0:00.0	You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology.
0:05.7	This podcast is intended for health care professionals only.
0:08.8	Any views expressed are the presenters' own and do not necessarily reflect the views of WebMD or Medscape.
0:14.9	Hi, everyone.
0:16.4	This is John Mandrola from the Heart.org Medscape Cardiology, and this is this week in cardiology for
0:22.8	November 7th, 2025. This week, I'll be discussing some listener feedback on non-culpate PCI in patients
0:30.9	with STEMI, a major, major cardiac result in patients with chronic kidney disease on hemodialysis, some news on
0:40.6	GLP-1 agonist, a dubious stroke trial, and an AHA preview.
0:47.6	So I received some pretty harsh feedback on my coverage last week of the non-significant
0:52.6	eye modern trial of FFR-guided non-culpate PCI at the time of
0:57.9	STEMI. In my discussion, I made the case that the non-significant results were entirely consistent with
1:04.3	the mountain of evidence that PCI does not reduce outcomes in patients with stable, stable disease over medical therapy.
1:13.3	What did not make sense to me was this guideline support of non-culpate PCI at the time of
1:18.9	STEMI. Why would PCI of a stable lesion over medical therapy alone not improve outcomes in
1:25.8	every setting except STEMI? So an RCA total occlusion in an inferior
1:32.3	MI, it coexist with an LAD lesion. It means that the RCA lesion is the acute lesion and the LAD is the
1:39.8	chronic lesion. How could PCI of that LAD improve outcomes when no other trial of stable lesions
1:48.6	has shown benefit to PCI over medical therapy? Now, I, modern trial, found no benefit for doing
1:55.9	the complete versus culprit-only revasperization. And when I discussed the trial last week, I supported my thesis
2:03.3	by appraising the Prammy trial, the complete and full revask trials. So the Prammy trial was
2:09.5	underpowered. The complete trial was positive, but it was driven only by an MI reduction. And of course,
2:16.0	it's very difficult to measure peri-procedural
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.